RxDoctor Payments Data

Luis Pena-Hernandez, MD

Pulmonary Disease · Atlantis, FLNPI 1457562159

Payments from drug & device makers

$205,349in general payments, 2019–2025

Across 704 payments — averaging $291.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$154K
  • Teva Pharmaceuticals USA, Inc.$26K
  • Gilead$10K
  • Intuitive Surgical$5K
  • AstraZeneca$3K
  • Boehringer Ingelheim$1K
  • plus $7K from 29 others

What the payments were for

  • Speaking & faculty fees$141,05086%
  • Travel & lodging$2,5492%
  • Food & beverage$15,1729%
  • Education$4,7513%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,349 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$410,763
Medicare patients
728
Services billed
4,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter583$779,239
Dupixent PenDupilumab107$421,036
OfevNintedanib Esylate30$388,725
NucalaMepolizumab61$245,391
TezspireTezepelumab-Ekko50$223,091
Breo ElliptaFluticasone/Vilanterol283$207,821
Breztri AerosphereBudesonide/Glycopyr/Formoterol119$152,614
SymbicortBudesonide/Formoterol Fumarate205$95,552
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$40,618
Stiolto RespimatTiotropium Br/Olodaterol Hcl45$38,192
Spiriva RespimatTiotropium Bromide25$27,973
Albuterol Sulfate HfaAlbuterol Sulfate702$21,531
Spiriva HandihalerTiotropium Bromide19$19,318
Advair HfaFluticasone Propion/Salmeterol19$19,018
Ambrisentan12$15,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta$153,591$1,273,070973 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$2,541$471,257374 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,159$454,890100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →